TIDMSLN
RNS Number : 0194X
Silence Therapeutics PLC
25 April 2019
Silence Therapeutics Strengthens Board with Key Appointments
Iain Ross appointed as Chairman of the Board of Directors
James Ede-Golightly appointed as a Non-Executive Director
April 25, 2019
LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the
Company") a leader in the discovery, development and delivery of
novel RNA therapeutics for the treatment of serious diseases, is
pleased to announce that Iain Ross has joined as a Non-Executive
Director and Chairman of the Board of Directors with immediate
effect. Silence also announces that James Ede-Golightly has joined
as a Non-Executive Director and that Stephen Parker is stepping
down as a Non-Executive Director, both with immediate effect.
Iain Ross is a highly experienced board director with a career
in the international life sciences and technology sectors that
spans 40 years. He held senior commercial roles at Sandoz, Fisons
and Hoffman La Roche before moving into the biotechnology sector
where he was Chairman and CEO of several international
biotechnology companies. Currently he is Non-executive Chairman at
Kazia Therapeutics Limited, e-Therapeutics plc and Redx Pharma plc.
Mr Ross is a qualified Chartered Director, Fellow of the Institute
of Directors and Honorary Fellow of Royal Holloway, London
University. He previously served as Chairman of the Board of
Silence Therapeutics, from 2005 to 2010.
James Ede-Golightly joins Silence with extensive experience in
finance, technology and company direction. He is currently Chairman
of DeepMatter Group Plc and Oxford Advanced Surfaces Ltd and
Non-executive Director at Oxehealth Limited. Mr Ede-Golightly was a
founder of ORA Capital Partners in 2006, prior to which he worked
as an analyst at Merrill Lynch Investment Managers and Commerzbank.
Mr Ede-Golightly is a Chartered Director, a Chartered Financial
Analyst and holds an MA in Economics from the University of
Cambridge. In 2012 Mr Ede-Golightly was awarded New Chartered
Director of the Year by the Institute of Directors.
Dr. David Horn Solomon, Chief Executive Officer of Silence
Therapeutics, commented:
"I'm very pleased to welcome Iain Ross and James Ede-Golightly
to the Board of Directors. Iain brings with him extensive
healthcare and governance experience and I am looking forward to
working with him to build significant value for shareholders,
patients and their caregivers. I would also like to thank Stephen
for his service as a valued Board member and advisor."
Iain Ross, Incoming Chairman of the Board of Directors at
Silence Therapeutics, commented:
"I am delighted to be returning to Silence Therapeutics and I
look forward to working with David, the new management team and all
stakeholders. With a renewed strategy in place and a return to the
clinic imminent I believe Silence now represents a fundamentally
transformed value proposition and I am excited to work with the
team and to bring some stability to the Board to deliver on its
potential."
The following information is disclosed pursuant to Schedule Two,
paragraph (g) of the AIM Rules for Companies:
Full name and age: Iain Gladstone Ross (aged 65)
Iain Ross does not currently hold any shares in Silence.
Current Directorships or Partnerships:
-- Biomer Technology Limited
-- E-Therapeutics plc
-- Gladstone Consultancy Partnership
-- Gladstone Partners Limited
-- Kazia Therapeutics Limited
-- Redx Anti-Infectives Ltd
-- Redx Immunology Limited
-- Redx MRSA Limited
-- Redx Oncology Ltd
-- Redx Pharma plc
-- Rosscard Leisure Limited
Previous Directorships or Partnerships:
-- Aldershot Town Football Club Limited
-- Amarantus Bioscience Holdings Inc
-- Anatara Life Sciences Ltd
-- Benitec Biopharma Limited
-- Factor Therapeutics Europe Limited
-- Pharminox Limited
-- Premier Veterinary Group plc
-- Smartspace Software plc
-- Tissue Therapies Limited
-- Yellowcross Limited
Iain Ross joined the board of Redx Pharma plc on 1 May 2017. On
24 May 2017, Redx Pharma plc and Redx Oncology Ltd were put into
administration by Liverpool City Council as a result of non-payment
of an outstanding loan of GBP2m and shares in Redx Pharma plc were
suspended. On 3 November 2017 Redx Pharma plc and Redx Oncology Ltd
exited administration with all creditors paid and trading in Redx
Pharma plc resumed, under the Chairmanship of Iain Ross.
No further information in connection with the appointment of
Iain Ross is required to be disclosed under Schedule Two, paragraph
(g) of the Aim Rules for Companies.
Full name and age: James Lawrence Ede-Golightly (aged 39)
James Ede-Golightly does not currently hold any shares in
Silence. James Ede-Golightly is a director of Serendipity Capital
Limited, a Guernsey registered company whose sole beneficiary is
Richard Griffiths. Serendipity Capital Limited holds 9,325,156
Silence shares. Richard Griffiths has an overall beneficial holding
of 20,952,867 shares (29.5%).
Current Directorships or Partnerships:
-- Deepmatter Group plc
-- Dunheved Limited
-- East Balkan Properties plc
-- Gulfsands Petroleum plc
-- Oxehealth Limited
-- Oxford Advanced Surfaces Limited
-- Sarossa plc
-- Serendipity Capital Limited
Previous Directorships or Partnerships:
-- Fermain Capital Limited
-- Gulfsands Petroleum Limited
-- Gulfsands Petroleum Holdings Ltd
-- Gulfsands Petroleum Tunisia Ltd
-- Gulfsands Petroleum Sud America Ltd
-- Gulfsands Petroleum Iraq Ltd
-- Gulfsands Petroleum MENA Ltd
-- Gulfsands Petroleum Levant Ltd
-- Gulfsands Petroleum Morocco Ltd (registered in the Cayman Islands)
-- Gulfsands Petroleum Morocco Ltd (registered in Cyprus)
-- Oraelean Trading Systems Ltd
-- ORA (Guernsey) Limited
-- ORA Limited (Jersey)
-- ORA Limited (Guernsey)
-- Osceola Production LLC
-- Osceola Royalties LLC
-- Plant Health Care plc
-- Quoram Limited
No further information in connection with the appointment of
James Ede-Golightly is required to be disclosed under Schedule Two,
paragraph (g) of the Aim Rules for Companies.
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457
Dr David Horn Solomon, Chief Executive Officer 6900
Iain Ross, Chairman
Peel Hunt LLP (Nominated Adviser and Broker) Tel: +44 (0)20 7418
James Steel/Oliver Jackson 8900
European IR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
US IR Tel: +1 (443) 213-0505
Westwicke Partners
Peter Vozzo
peter.vozzo@westwicke.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural
mechanism of RNA interference, or RNAi, within its cells. Its
proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using
its enabling delivery systems, it has achieved an additional
level of specificity by delivering its
therapeutic RNA molecules exclusively to target cells. Silence's
proprietary RNA chemistries and
delivery systems are designed to improve the stability of our
molecules and enhance effective delivery
to target cells, providing a powerful modular technology well
suited to tackle life-threatening diseases.
For more information, please visit:
https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAFZLLLKZFXBBB
(END) Dow Jones Newswires
April 25, 2019 02:01 ET (06:01 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024